Skip to main content

Advertisement

SpringerLink
Log in

Quality of Life and Survivorship in Lymphoma

  • Lymphomas (T Hilal, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

With an increasing number of long-term lymphoma survivors, there has been emphasis on optimizing quality of life and identifying survivorship challenges. This review summarizes the latest advancements pertaining to health-related quality of life and survivorship in lymphoma.

Recent Findings

Quality of life can vary from diagnosis through survivorship though some physical, social, and emotional effects may be persistent. Incorporation of patient reported outcomes enables recognition of factors that significantly impact quality of life. A greater understanding of quality of life and survivorship issues has generated momentum for practice change, improving education, and designing behavior related interventions.

Summary

Patients with lymphoma face many challenges as they navigate their cancer experience. There is a tremendous opportunity to build upon this work through well-designed prospective longitudinal studies aimed at identifying vulnerable patient groups and impactful points of intervention during survivorship.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Surveillance E, and End Results Program. Cancer Stat Facts: Non-Hodgkin Lymphoma 2011–2017. Available from: https://seer.cancer.gov/statfacts/html/nhl.html. Accessed 3/4/22.

  2. Surveillance E, and End Results Program. Cancer Stat Facts: Hodgkin Lymphoma 2011–2017. Available from: https://seer.cancer.gov/statfacts/html/hodg.html. Accessed 3/4/22.

  3. Denlinger CS, Carlson RW, Are M, Baker KS, Davis E, Edge SB, et al. Survivorship: introduction and definition. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014;12(1):34–45.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cella D, Webster K, Cashy J, Kutikova L, Burgess MF, Lin BK, et al. Development of a measure of health-related quality of life for non-hodgkin’s lymphoma clinical research: the functional assessment of cancer therapy - lymphoma (FACT-Lym). Blood. 2005;106(11):750.

    Article  Google Scholar 

  5. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.

    Article  CAS  PubMed  Google Scholar 

  6. Hlubocky FJ, Webster K, Beaumont J, Cashy J, Paul D, Abernethy A, et al. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the national comprehensive cancer network-functional assessment of cancer therapy - lymphoma symptom index. Leuk Lymphoma. 2013;54(9):1942–6.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization For Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    Article  CAS  PubMed  Google Scholar 

  8. Cella D, Choi SW, Condon DM, Schalet B, Hays RD, Rothrock NE, et al. PROMIS(®) adult health profiles: efficient short-form measures of seven health domains. Value Health. 2019;22(5):537–44.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  11. Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 national cutaneous lymphoma foundation survey. Cancer. 2006;107(10):2504–11.

    Article  PubMed  Google Scholar 

  12. Engin B, Keçici AS, Uzun A, Yalçın M. Psychiatric comorbidity, depression, and anxiety levels and quality of life of the patients with mycosis fungoides. Dermatol Ther. 2020;33(6):e13922.

    Article  PubMed  Google Scholar 

  13. • Ottevanger R, van Beugen S, Evers AWM, Willemze R, Vermeer MH, Quint KD. Quality of life in patients with mycosis fungoides and Sézary syndrome: a systematic review of the literature. J Eur Acad Dermatol Venereol. 2021;35(12):2377–87. This systemic review nicely summarizes the unique HRQOL issues faced by a vulnerable set of NHL patients - those with cutaneous T cell lymphomas.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Singh JA, Satele D, Pattabasavaiah S, Buckner JC, Sloan JA. Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales. Health Qual Life Outcomes. 2014;12:187.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Thompson CA, Yost KJ, Maurer MJ, Allmer C, Farooq U, Habermann TM, et al. Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol. 2018;36(5):749–56.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Jerkeman M, Kaasa S, Hjermstad M, Kvaløy S, Cavallin-Stahl E. Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic lymphoma group trial. Med Oncol. 2001;18(1):85–94.

    Article  CAS  PubMed  Google Scholar 

  17. Jung HA, Park S, Cho JH, Kim S, Ko YH, Kim SJ, et al. Prognostic relevance of pretreatment quality of life in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP: results from a prospective cohort study. Ann Hematol. 2012;91(11):1747–56.

    Article  CAS  PubMed  Google Scholar 

  18. Lindberg Å, Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbaek K, Geisler CH, Jerkeman M. Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience. Hematol Oncol. 2022;40(1):22–30. https://doi.org/10.1002/hon.2940.

  19. •• Kreissl S, Müller H, Goergen H, Meissner J, Topp M, Sökler M, et al. Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin study group. J Clin Oncol. 2020;38(25):2839–48. This is a large analysis of HL patients of all stages that highlights some of the persistent survivorship related issues in this highly curable type of lymphoma. It also points out that poor HRQOL scores at diagnosis may be indicative of poor HRQOL into survivorship.

    Article  PubMed  Google Scholar 

  20. Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman E, Cherin E, et al. Quality of life assessment of Hodgkin’s disease survivors: a model for cooperative clinical trials. Oncology. 1990;4(5):93–101; discussion 4.

    CAS  PubMed  Google Scholar 

  21. Kornblith AB, Anderson J, Cella DF, Tross S, Zuckerman E, Cherin E, et al. Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B. Cancer. 1992;70(8):2214–24.

    Article  CAS  PubMed  Google Scholar 

  22. Kornblith AB, Herndon JE 2nd, Zuckerman E, Cella DF, Cherin E, Wolchok S, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin’s disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol. 1998;9(3):297–306.

    Article  CAS  PubMed  Google Scholar 

  23. Oerlemans S, Mols F, Nijziel MR, Zijlstra WP, Coebergh JW, van de Poll-Franse LV. The course of anxiety and depression for patients with Hodgkin’s lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry. J Cancer Surviv. 2014;8(4):555–64.

    Article  PubMed  Google Scholar 

  24. •• Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2022;6(2):590–9. This study was potentially practice changing in relapsed refractory HL based on PFS alone however the incorporation of PROs really drove home the importance of considering the impact of treatment from the patient's perspective.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–44.

    Article  CAS  PubMed  Google Scholar 

  26. Davies A, Trask P, Demeter J, Florschütz A, Hänel M, Kinoshita T, et al. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. Ann Hematol. 2020;99(12):2837–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Patrick DL, Powers A, Jun MP, Kim Y, Garcia J, Dehner C, et al. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. Blood Adv. 2021;5(8):2245–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, et al. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(4):629–37.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Tedeschi RG, Calhoun LG. The posttraumatic growth inventory: measuring the positive legacy of trauma. J Trauma Stress. 1996;9(3):455–71.

    Article  CAS  PubMed  Google Scholar 

  30. Matheson L, Boulton M, Lavender V, Collins G, Mitchell-Floyd T, Watson E. The experiences of young adults with Hodgkin lymphoma transitioning to survivorship: a grounded theory study. Oncol Nurs Forum. 2016;43(5):E195-e2014.

    Article  PubMed  Google Scholar 

  31. Drost FM, Mols F, Kaal SE, Stevens WB, van der Graaf WT, Prins JB, et al. Psychological impact of lymphoma on adolescents and young adults: not a matter of black or white. J Cancer Surviv. 2016;10(4):726–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Husson O, Prins JB, Kaal SE, Oerlemans S, Stevens WB, Zebrack B, et al. Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. Acta Oncol. 2017;56(2):288–94.

    Article  PubMed  Google Scholar 

  33. Revenson TA, Schiaffino KM, Majerovitz SD, Gibofsky A. Social support as a double-edged sword: the relation of positive and problematic support to depression among rheumatoid arthritis patients. Soc Sci Med. 1991;33(7):807–13.

    Article  CAS  PubMed  Google Scholar 

  34. Geue K, Götze H, Friedrich M, Leuteritz K, Mehnert-Theuerkauf A, Sender A, et al. Perceived social support and associations with health-related quality of life in young versus older adult patients with haematological malignancies. Health Qual Life Outcomes. 2019;17(1):145.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Degner LF, Sloan JA. Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage. 1995;10(6):423–31.

    Article  CAS  PubMed  Google Scholar 

  36. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.

    Article  CAS  PubMed  Google Scholar 

  37. Roper K, Cooley ME, McDermott K, Fawcett J. Health-related quality of life after treatment of Hodgkin lymphoma in young adults. Oncol Nurs Forum. 2013;40(4):349–60.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ruark J, Mullane E, Cleary N, Cordeiro A, Bezerra ED, Wu V, et al. Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant. 2020;26(1):34–43.

    Article  PubMed  Google Scholar 

  39. Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2006;56(6):323–53.

    Article  PubMed  Google Scholar 

  40. Pophali PA, Larson MC, Rosenthal AC, Robinson D, Habermann TM, Thanarajasingam G, et al. The association of health behaviors with quality of life in lymphoma survivors. Leuk Lymphoma. 2021;62(2):271–80.

    Article  PubMed  Google Scholar 

  41. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77(4):371–83.

    Article  PubMed  Google Scholar 

  42. Spector DJ, Noonan D, Mayer DK, Benecha H, Zimmerman S, Smith SK. Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma? Cancer. 2015;121(18):3343–51.

    Article  PubMed  Google Scholar 

  43. Bellizzi KM, Rowland JH, Arora NK, Hamilton AS, Miller MF, Aziz NM. Physical activity and quality of life in adult survivors of non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(6):960–6.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Courneya KS, Sellar CM, Stevinson C, McNeely ML, Peddle CJ, Friedenreich CM, et al. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol. 2009;27(27):4605–12.

    Article  PubMed  Google Scholar 

  45. Streckmann F, Kneis S, Leifert JA, Baumann FT, Kleber M, Ihorst G, et al. Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy. Ann Oncol. 2014;25(2):493–9.

    Article  CAS  PubMed  Google Scholar 

  46. Park ER, Traeger L, Vranceanu AM, Scult M, Lerner JA, Benson H, et al. The development of a patient-centered program based on the relaxation response: the relaxation response resiliency program (3RP). Psychosomatics. 2013;54(2):165–74.

    Article  PubMed  Google Scholar 

  47. • Perez GK, Walsh EA, Quain K, Abramson JS, Park ER. A virtual resiliency program for lymphoma survivors: helping survivors cope with post-treatment challenges. Psychol Health. 2021;36(11):1352–67. This study is a rare example of a lymphoma focused mind body interventional therapy resulting in patient reported better coping skills. More such studies are needed.

    Article  PubMed  Google Scholar 

  48. Ganz PA. Late effects of cancer and its treatment. Semin Oncol Nurs. 2001;17(4):241–8.

    Article  CAS  PubMed  Google Scholar 

  49. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci. 2003;58(1):82–91.

    Article  PubMed  Google Scholar 

  50. Network NCC. Survivorship (Version 3.2021) 2021. Available from: https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf. Accessed 3/4/22.

  51. Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099–108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Chakraborty R, Hill BT, Majeed A, Majhail NS. Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transplant Cell Ther. 2021;27(3):222–9.

    Article  CAS  PubMed  Google Scholar 

  53. Conybeare D, Behar E, Solomon A, Newman MG, Borkovec TD. The PTSD Checklist-Civilian Version: reliability, validity, and factor structure in a nonclinical sample. J Clin Psychol. 2012;68(6):699–713.

    Article  PubMed  Google Scholar 

  54. LeBlanc MR, Zimmerman S, LeBlanc TW, Bryant AL, Hudson KE, Smith SK. Persistent fatigue among long-term non-Hodgkin lymphoma survivors. Leuk Lymphoma. 2022;63(2):344–352. https://doi.org/10.1080/10428194.2021.1984450.

  55. Howell D, Keller-Olaman S, Oliver TK, Hack TF, Broadfield L, Biggs K, et al. A pan-Canadian practice guideline and algorithm: screening, assessment, and supportive care of adults with cancer-related fatigue. Curr Oncol. 2013;20(3):e233–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, et al. Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group Study 9133. J Clin Oncol. 2003;21(18):3512–9.

    Article  PubMed  Google Scholar 

  57. Daniëls LA, Oerlemans S, Krol AD, Creutzberg CL, van de Poll-Franse LV. Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity. Br J Cancer. 2014;110(4):868–74.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Ng AK, Li S, Recklitis C, Neuberg D, Chakrabarti S, Silver B, et al. A comparison between long-term survivors of Hodgkin’s disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol. 2005;16(12):1949–55.

    Article  CAS  PubMed  Google Scholar 

  59. Knobel H, Håvard Loge J, Lund MB, Forfang K, Nome O, Kaasa S. Late medical complications and fatigue in Hodgkin’s disease survivors. J Clin Oncol. 2001;19(13):3226–33.

    Article  CAS  PubMed  Google Scholar 

  60. Oldervoll LM, Kaasa S, Knobel H, Loge JH. Exercise reduces fatigue in chronic fatigued Hodgkins disease survivors–results from a pilot study. Eur J Cancer. 2003;39(1):57–63.

    Article  CAS  PubMed  Google Scholar 

  61. Liu L, He X, Feng L. Exercise on quality of life and cancer-related fatigue for lymphoma survivors: a systematic review and meta-analysis. Support Care Cancer. 2019;27(11):4069–82.

    Article  PubMed  Google Scholar 

  62. McCabe MS, Bhatia S, Oeffinger KC, Reaman GH, Tyne C, Wollins DS, et al. American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. J Clin Oncol. 2013;31(5):631–40.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Mayer DK, Birken SA, Check DK, Chen RC. Summing it up: an integrative review of studies of cancer survivorship care plans (2006–2013). Cancer. 2015;121(7):978–96.

    Article  PubMed  Google Scholar 

  64. Viscuse P, Yost KJ, Jenkins S, Lackore K, Habermann T, Thanarajasingam G, et al. Impact of lymphoma survivorship clinic visit on patient-centered outcomes. J Cancer Surviv. 2019;13(3):344–52.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA

    Allison Rosenthal

Authors
  1. Allison Rosenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Allison Rosenthal.

Ethics declarations

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Conflict of Interest

The author declares no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Lymphomas

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosenthal, A. Quality of Life and Survivorship in Lymphoma. Curr Oncol Rep 24, 1113–1120 (2022). https://doi.org/10.1007/s11912-022-01283-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-022-01283-3

Keywords

Search

Navigation